logo
Fossilized fish up to 16 million years old found in Australia, with last meal still intact

Fossilized fish up to 16 million years old found in Australia, with last meal still intact

CNN28-03-2025

Summary
Paleontologists discovered a fossilized fish species dating back up to 16 million years with its last meal intact.
Named Ferruaspis brocksi, the fish was preserved in goethite, allowing researchers to examine its stomach contents.
Analysis revealed the fish primarily fed on phantom midge larvae and provided first evidence of Osmeriformes in Australia.
The fossil showed pigmented cells, giving insight into the fish's coloration and possible shoaling behavior to evade predators.
The discovery suggests this freshwater species thrived in what was once a lush rainforest environment during the Miocene Epoch. Paleontologists have discovered a newly identified fish species in Australia so well-preserved that they could determine its last meal — dating back up to 16 million years to the Miocene Epoch.
Researchers unearthed the fossilized freshwater fish, named Ferruaspis brocksi, at the McGraths Flat site in central New South Wales, according to a study published March 17 in the Journal of Vertebrate Paleontology.
The study team excavated multiple fossils containing F. brocksi, each entombed in goethite, an iron-rich mineral that maintained the fish in extraordinary detail. This rare fossilization process allowed researchers to examine the species' structural features, including its soft tissue, stomach and coloration patterns.
'Every time I have a detailed look at a fossil from McGraths Flat, I am amazed by its detailed preservation,' study coauthor Dr. Michael Frese, associate professor and virologist at the University of Canberra, said via email. 'It's very surprising, (and) it's extremely rare to be able to tell the colour of a fossil fish like this.'
Beyond identifying a newfound species, researchers uncovered the first detailed evidence of Osmeriformes, a group that includes modern-day graylings and smelts, in Australia.
Until now, scientists could only speculate when smelts first arrived on the continent due to a lack of fossil evidence, but this new finding offers crucial insights into the region's ancient ecosystem, Frese said.
Tracing a prehistoric food web
Using high-powered microscopes, paleontologists analyzed the stomach contents and intestinal tract of F. brocksi and found the fish primarily fed on various types of phantom midge larvae — an almost transparent insect larvae — along with insect wings and even a small bivalve, or a mollusk with hinged shells.
'Knowing their diet helps us start to paint a picture of food chains and food webs in the original environments,' said Dr. Anthony Martin, a professor of practice in the department of environmental sciences at Emory University in Atlanta, who was not involved in the study.
One specimen of fish had a freshwater mussel attached to its tail fin. The finding is rare because the lake sediments where F. brocksi were found wouldn't have supported an environment for the bivalve to reach sexual maturity and produce glochidia — the larval, parasitic stage of some freshwater mussels, Frese said. He added that it's likely the parasites infected the fish in a nearby river, suggesting a connection between the fossil site and a neighboring waterway.
The stomach contents not only helped paleontologists identify what the fish were eating but also when they were feeding.
'Many extant species of Chaoborus (phantom midge larvae) do not occur in lakes with fishes, and those that do co-exist with fishes often conduct a diurnal migration to avoid predatory fishes during the daytime,' Frese said.
'As most Chaoborus larvae spent most of the day in the sediment, hiding from pelagic predators, F. brocksi would likely have preyed on Chaoborus at night.'
A glimpse into history
One of the most surprising discoveries was the presence of melanophores or pigmented cells, offering insight into the fish's coloration.
The fossils revealed F. brocksi had a slender body, similar to modern-day smelts. The fish also presented evidence of countershading, in which the animal was darker on the top and lighter on its stomach, with two stripes running along the length of its body, according to the study.
Frese noted that this coloration pattern may indicate a shoaling behavior, in which fish gather in loose social groups. The countershading also likely helped the species evade predators from above, Martin added.
While central New South Wales is now characterized by plains and plateaus, during the Miocene, the region was surrounded by lush rainforests, according to the study. The discovery of F. brocksi west of the Great Dividing Range suggests that, unlike most surviving Osmeriformes, this species may have spent its entire life in freshwater, according to the study.
'While this study is focused on one species of fish,' Frese said, 'it is part of a broader ecosystem that we are piecing together by excavating fossils from the site.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

At-home health tests are here. But they aren't always the best option
At-home health tests are here. But they aren't always the best option

Yahoo

time5 days ago

  • Yahoo

At-home health tests are here. But they aren't always the best option

The doctor is in — the mailbox, that is. You can now do self-administered tests for everything from thyroid function to HIV in the privacy of your own home — and that list continues to grow, as the Food and Drug Administration recently approved the first at-home cervical cancer test. While the tests can make it easier for people to access health care and can be helpful for those who have extreme anxiety about sensitive or invasive medical exams, experts warn that most of the tests cannot replace an actual in-person visit. Here's what doctors say you can test for at home, and when you should make the trek to your physician's office. What kinds of at-home tests are available? There are two kinds at 'at-home tests.' In one type, the patient collects the sample and sends it off to a lab; the new cervical cancer test is like this. The other gives an instant result — think COVID-19 and pregnancy tests. What are the benefits of at-home tests? HIV home-testing kits can improve rates of diagnosing sexually transmitted infections in rural communities and help people who are nervous about going to the doctor to seek a sensitive test, said Dr. Joseph Cherabie, an infectious diseases specialist in St. Louis. 'You really want to get people to care as quickly as possible, but some people could be very anxious about that results as well," Cherabie said. "And they have very negative reactions.' Labs are required to report a positive HIV test, instead of putting the onus on the patient who took the test, Cherabie said, and and, often, the patient is matched up with HIV support services. 'If you are part of a sexual and gender minority community, going to a doctor's office can be full of a lot of historical trauma, and you may prefer to just do testing at home without anyone judging you or asking you invasive questions about your sex life,' Cherabie said. The new cervical cancer test — which tests for strains of human papillomavirus, or HPV — involves a testing swab that's like a tampon, said Dr. Susan Modesitt, a gynecologic oncologist at Emory University in Atlanta. It is not, Modesitt said, a replacement for a Pap smear, the exam in which a metal speculum is inserted in the vagina to scrape cervix cells. A doctor's visit also involves a pelvic exam, a chance to talk about abnormal bleeding — a sign of endometrial cancer — and other symptoms and issues, like menopause or STIs. 'There are so many other reasons to see your doctor and get an exam outside of a cervical cancer screening,' she said. I live in a rural area — can I take an at-home test? Some at-home tests can replace a trip to the doctor's office. That's especially true in rural areas, where it can be difficult to get a colonoscopy. 'The colonoscopy requires a pre-op, and you have to drive maybe 70 miles for it,' said Dr. Steven Furr, board chair of the American Academy of Family Physicians who practices in rural Alabama. 'You get anesthesia. It's actually almost like a surgical procedure in many ways. "So, for a lot of people, that's pretty arduous. That's where an at-home test can come in handy.' But, Furr said, if your test reveals issues, you need to go to your doctor. Plus, patients should always discuss test results with their physician instead of interpreting them on their own, he said. Who shouldn't do at-home tests? If you have symptoms of what you're testing for, go to the doctor. At-home colon cancer tests aren't the right option for people with a history of colon cancer or high-risk conditions, such as inflammatory bowel disease, said Dr. Zachariah Foda, a gastroenterologist at Johns Hopkins. He added that they're also not recommended for people who are having GI symptoms. While there are tests for many things — running anywhere from $15 to $400, depending on what is being evaluated — Furr said it's essential to make sure that your test is FDA-approved so you can better trust the results. 'Anytime we get people involved in their own health care and help them understand what's going on, I think that's a good thing and it gives us a chance to talk,' he said. 'Any kind of screening is better than no screening.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Devna Bose, The Associated Press Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Yahoo

time27-05-2025

  • Yahoo

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies in the neoadjuvant setting that are associated with improved pathologic response in patients with head and neck cancer. Lead investigator and collaborator, Conor Steuer, MD from Winship Cancer Center at Emory University, will present results at the 2025 Annual Meeting of Clinical Oncology (ASCO) in Chicago on June 1, 2025. ASCO Conference Information: Date: Sunday, June 1, 2025 Presentation title: Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer. Abstract 103. Time: 9:45-11:15 AM CST/10:45 AM – 12:15 PM EST. Session Title: Clinical Science Symposium – Turning 'Cold' Tumors 'Hot' Previously reported data from our collaboration with Emory University suggest a crucial role of pepinemab treatment in melanoma patients to facilitate immune cell interactions within highly organized and robust centers of immunity, called tertiary lymphoid structures, or TLS. By blocking the SEMA4D inhibitory signal to Dendritic Cells (DC), pepinemab allows productive, coordinated interactions between SEMA4D+ T cells, key effector cells capable of eradicating tumors, and DC, regulatory cells that promote immune cell interactions within TLS so as to amplify mature T cell responses. New data presented at ASCO will characterize the mechanisms of neoadjuvant treatment with pepinemab in patients with resectable head and neck cancer (HNSCC). Standard of care for these patients often involves toxic chemotherapy and/or radiotherapy, in addition to surgery, which can significantly impact their quality of life. Peri-operative treatment with immunotherapy has recently reported promising and potentially practice-changing results. Certain HNSCC with hot beds of immune cells organized into TLS have been shown to correlate with clinical benefit and positive response to immune checkpoint therapy. However, many HNSCC are considered immunologically 'cold' tumors, due to exclusion of immune cells from tumor and/or high levels of immune suppressor cells, making them resistant to immune checkpoint therapy. Pepinemab has potential to be a major advance for HNSCC patients with cold and resistant disease, with capacity of a well-tolerated and effective treatment that can induce formation and harness the power of TLS to optimize the clinical benefit of immunotherapy. Our data demonstrate that the addition of pepinemab to neoadjuvant immune checkpoint treatments did not compound toxicities, yet it enhanced TLS maturity that correlated with improved pathologic response. Collectively, these results highlight the potential of pepinemab to turn immunologically cold tumors, such as HPV-negative head and neck cancer, into hot immune centers by inducing robust and mature TLS. About PepinemabPepinemab is a humanized IgG4 monoclonal antibody designed to block SEMA4D, which can otherwise bind to plexin-B1 receptors to trigger collapse of the actin cytoskeleton and lead to loss of homeostatic functions of dendritic cells in immune tissue and of astrocytes and other glial cells in the brain. Pepinemab appears to be well-tolerated with a favorable safety profile in multiple clinical trials in different cancer and neurological indications. About Vaccinex Inc. Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents infiltration and activation of immune cells in tumors and triggers damaging inflammation in neurodegenerative diseases. In oncology, pepinemab is also being evaluated in combination with KEYTRUDA® in the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO® in a Phase 1b/2 study in patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma. We believe pepinemab has also given promising results as a monotherapy in the Phase 1b/2 SIGNAL-AD study in Alzheimer's Disease, and the Company has previously published promising Phase 2 data suggesting a slowing of cognitive decline in Huntington's disease. Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ, USA. Additional information about the study is available at: KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. BAVENCIO®/avelumab is provided by Merck KGaA, Darmstadt, Germany, previously as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer. Forward Looking StatementsTo the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. ('Vaccinex,' 'we,' 'us,' or 'our'), they are forward-looking statements reflecting management's current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of the KEYNOTE-B84 and SIGNAL-AD clinical trials; the use and potential benefits of pepinemab in R/M HNSCC, lung cancer, metastatic pancreatic adenocarcinoma (PDAC) and other indications; the potential for benefits as compared to single agent KEYTRUDA® or BAVENCIO®; expectations with respect to the collaboration of Merck,; and other statements identified by words such as 'anticipate,' 'believe,' 'plans,' 'schedule,' 'being,' 'will,' 'appears,' 'expect,' 'ongoing,' 'potential,' 'promising,' 'suggest', and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical studies and clinical trials, that interim and preliminary data may not be predictive of final results and does not ensure success in later clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, the Company assumes no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled 'Risk Factors' in our previous reports filed with the Securities and Exchange Commission and the other risks and uncertainties described in the Company's 2024 year-end Form 10-K filed with the SEC. CONTACT: Investor Contact Elizabeth Evans, PhD Chief Operating Officer Senior Vice President, Vaccinex, Inc. (585) 271-2700 eevans@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

New smartphone app screens for a concerning blood condition — using a photo of your fingernails
New smartphone app screens for a concerning blood condition — using a photo of your fingernails

New York Post

time22-05-2025

  • New York Post

New smartphone app screens for a concerning blood condition — using a photo of your fingernails

They're trying to put the 'cure' in manicure. Researchers from Emory University and Georgia Tech developed a smartphone app to screen for anemia using images of a person's fingernail beds instead of the conventional blood test. Anemia, which is believed to affect over 2 billion people worldwide, occurs when someone does not have enough healthy red blood cells or hemoglobin to carry oxygen to the body's tissues. 3 Iron deficiency has been called one of the world's most widespread nutritional problems. Chanelle2000/ – The color of the fingernail bed reflects the amount of hemoglobin in the blood. Hemoglobin is the protein in red blood cells that carries oxygen through the body and gives blood its signature red hue. When hemoglobin levels drop, fingernail beds appear paler. The AI-powered algorithm in the new app was tested on over 9,000 users, whose fingernail selfies were compared to their clinical blood test results. Within seconds of submitting a fingernail photo, the tech estimated hemoglobin levels with remarkable accuracy. When using a hemoglobin threshold of 12.5 g/dL to identify anemia, the app achieved 89% sensitivity and 93% specificity, numbers on par with traditional screening methods. For those with chronic anemia, there's a 'personalization feature' in the app that can be calibrated to a user's baseline by entering lab-confirmed hemoglobin results alongside the app's estimates. After personalization, the app's performance approached levels seen in medical devices cleared by the Food and Drug Administration for non-invasive hemoglobin measurement. Results from this study were published this month in the Proceedings of the National Academy of Sciences. 3 The color of the fingernail bed reflects the amount of hemoglobin in the blood. Design Cells – The technology, now licensed to Sanguina, has been made publicly available for download and used more than 1.4 million times in the US. Traditional anemia testing requires blood work, lab access, and, in most cases, insurance coverage. The team behind the app is hopeful that it will prove revolutionary for those with chronic conditions like kidney disease, cancer or nutritional deficiencies that require regular hemoglobin monitoring. Symptoms of anemia include fatigue, weakness, cold extremities, chest pain, pale skin, loss of appetite, shortness of breath, lightheadedness, headaches and cravings for non-nutritional objects like ice, soil, paper and even clay. 3 Researchers maintain that their new app is not intended to replace medical care but to support screening and monitoring, particularly for those with chronic anemia and those living in remote or underserved communities. webbiz – Widespread use of the app has revealed geographic and demographic anemia patterns. Android users, who typically spend less on their devices than iPhone users, showed lower hemoglobin levels, suggesting a link between income and anemia. Further analysis shows that places with higher median incomes, higher percentages of black residents, larger populations and more primary care physicians per resident had more app users. Researchers maintain that the app is not intended to replace medical care but to support screening and monitoring, particularly for those with chronic anemia and those living in remote or underserved communities. And screening has never been more critical. Iron deficiencies like anemia compromise the immune system, making it harder for the body to fight illness. Further, research has found that anemia is present in 30% to 75% of colorectal cancer patients.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store